REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the fourth quarter and year ended December 31, 2024.

Regenxbio closes strategic partnership with Nippon Shinyaku for MPS diseases: Rockville, Maryland Wednesday, March 5, 2025, 14:00 Hrs [IST] Regenxbio Inc., a leading clinical-stag ...

MPS disorders are inherited in an autosomal recessive manner, except for MPS II (Hunter syndrome), which is X-linked. Symptoms vary depending on the specific type of MPS but commonly include ...

REGENXBIO Inc.  today announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the agreement, REGENXBIO and Nippon Shinyaku will develop and ...

Denali Therapeutics DNLI reported primary analysis data from an early to mid-stage study of its pipeline candidate, tividenofusp alfa (DNL310), in 47 patients with Hunter syndrome (MPS II ...

Regenxbio (RGNX) announced the closing of its previously announced strategic partnership with Nippon Shinyaku. Under the terms of the ...

DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for ...

Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...